Health Condition 1: I501- Left ventricular failure, unspecified
Conditions
Interventions
Intervention1: Dapagliflozin: Patient in dapaglilflozin will be given the dosage 10 mg and will be escalated as per physician discretion.
Control Intervention1: Sacubitril Valsartan: Patient in the Sa
Sponsors
All India Institute Of Medical Sciences, Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients Age 18 year to 75 years of either sex. 2. Left Ventricular ejection fraction 3. Patient having Heart failure belonging to NYHA class II-III
Exclusion criteria
Exclusion criteria: 1.Patient having Acute decompensated Heart failure. 2.Patient who have eGFR 3.Patient with history of intolerance to SGLT-2 inhibitor or ARNI (Angiotensin receptor-neprilysin inhibitor) 4.Patients having AST/ALT =3 times of normal range 5.Pregnant and lactating women. 6.Patient with recurrent Urinary Tract Infections. 7.Patient having recent Pyelonephritis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in NT-proBNP from baseline to 16 weeks.Timepoint: baseline, 4th week and 16 th week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Mean change in Kansas City Cardiomyopathy Questionnaire (KCCQ) points from baseline to 16 weeks 2.Mean change in eGFR, GDF-15 and ECHO findings (Left ventricular ejection fraction, End diastolic volume) from baselines to 16 weeks 3.Cost Needed to Treat (CNT) to prevent one event of CVD. 4. Safety analysis between the two groups. Timepoint: baseline, 4th week , 16 th week | — |
Countries
India
Contacts
Public ContactDr Krishna Tiwari
All India Institute Of Medical Sciences,Jodhpur
Outcome results
None listed